جميع الدراسات
التسجيل عن طريق الدعوةرَصْدِيّ

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

This important study is designed for adult men in the UK living with haemophilia B. It's a long-term follow-up for those who previously took part in earlier studies (CSL222_2001 or CSL222_3001) where they received a gene therapy treatment called etranacogene dezaparvovec. The main purpose is to see how safe the treatment remains over many years and how effective it continues to be in managing their haemophilia B. By carefully monitoring participants, researchers hope to gain a better understanding of the lasting effects of this innovative treatment, which could ultimately help improve future care for people with this condition.

نظرة سريعة

الحالة
التسجيل عن طريق الدعوة
الراعي
CSL Behring
الهدف من التسجيل
56
ابدأ
30 أغسطس 2023
التاريخ المتوقع للانتهاء
23 Mar 2035

ما هو موضوع هذه الدراسة؟

This study is a follow-up for adult men with haemophilia B who have already received a special gene therapy. Haemophilia B is a lifelong bleeding disorder where your blood doesn't clot properly due to a missing or faulty ‘Factor IX’ protein. Gene therapy like etranacogene dezaparvovec aims to provide instructions to your body to make this missing protein, potentially reducing bleeding episodes.

This particular study isn't offering new treatment; instead, it's looking at the long-term effects for people who have already had this gene therapy. Researchers want to understand if the treatment continues to be safe over many years and if it keeps working effectively to help manage haemophilia B. This is really important because gene therapies are relatively new, and understanding their long-term impact helps doctors and scientists make informed decisions about their wider use.

By carefully checking on the health and progress of these participants, the study contributes valuable information. It helps build a bigger picture of how this treatment works in the real world, beyond the initial trials. This knowledge is crucial for advancing our understanding of haemophilia B and developing even better therapies in the future.

النقاط الرئيسية

  • This is a long-term follow-up study for men with haemophilia B.
  • Participants have already received a gene therapy called etranacogene dezaparvovec.
  • The study aims to understand the long-term safety and effectiveness of the treatment.
  • No new medication is given; it involves regular monitoring and health checks.
  • Your participation helps improve future care for haemophilia B patients.

من قد يكون مؤهلاً؟

To be considered for this study, you must be an adult male who previously participated in one of the original treatment trials for etranacogene dezaparvovec – specifically, study CSL222_2001 or study CSL222_3001.

Additionally, you must have either fully completed your participation in one of those earlier studies, or at least five years must have passed since you received the etranacogene dezaparvovec gene therapy in one of those trials.

There are no other specific reasons listed that would prevent you from joining this follow-up study, provided you meet the criteria above.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. I am an adult male (aged 18 or over).
  2. I was previously treated with etranacogene dezaparvovec (CSL222) in study CSL222_2001 or CSL222_3001.
  3. I completed my participation in one of those earlier studies.
  4. OR at least 5 years have passed since I received the CSL222 treatment.
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part, you'll be regularly monitored by a medical team. This will involve scheduled visits to the clinic where you'll have various health checks. These typically include blood tests to measure your Factor IX levels and check your general health, physical examinations, and questions about any bleeding episodes or your overall well-being. You won't be receiving new medication as part of this study; it's purely for observation. The total duration of your participation will depend on how long ago you received the gene therapy, as the study aims to track participants for many years after their initial treatment.

المخاطر والفوائد المحتملة

Participating in this study offers a potential benefit of ongoing, close medical supervision of your health, particularly regarding your haemophilia B and the effects of the gene therapy you received. You would also be contributing valuable information that could help others living with haemophilia B in the future. As you have already received the treatment, the direct risks from the treatment itself are not new, but any long-term monitoring study involves regular clinic visits, which can be time-consuming, and blood tests, which carry minimal risks like bruising. You are free to withdraw from the study at any time without needing to give a reason, and this will not affect your usual medical care.

المواقع (28)

  • 10-15 Phoenix Childrens Hospital
    الرمز البريدي المؤكد
    فينيكس، الولايات المتحدة
  • 10-14 Arkansas Children's Hospital - Pharmacology
    الرمز البريدي المؤكد
    ليتل روك، الولايات المتحدة
  • 10-22 Orthopaedic Institute for Children
    الرمز البريدي المؤكد
    لوس أنجلوس، الولايات المتحدة
  • 10-21 Children's Hospital of Los Angeles
    الرمز البريدي المؤكد
    لوس أنجلوس، الولايات المتحدة
  • 10-63 UC Davis Medical Center
    الرمز البريدي المؤكد
    ساكرامنتو، الولايات المتحدة
  • 10-12 University of California, San Diego (UCSD)
    الرمز البريدي المؤكد
    سان دييغو، الولايات المتحدة
  • 10-25 University of Colorado Denver
    الرمز البريدي المؤكد
    أورورا، الولايات المتحدة
  • 10-19 University of South Florida
    الرمز البريدي المؤكد
    تامبا، الولايات المتحدة
  • 10-10 University of Michigan Medical Center
    الرمز البريدي المؤكد
    آن آربر، الولايات المتحدة
  • 10-16 University of North Carolina at Chapel Hill
    الرمز البريدي المؤكد
    تشابل هيل، الولايات المتحدة
  • 10-18 Oregon Health & Science University
    الرمز البريدي المؤكد
    بورتلاند، الولايات المتحدة
  • 10-20 Vanderbilt University Medical Center
    الرمز البريدي المؤكد
    ناشفيل، الولايات المتحدة

أسئلة شائعة

What is haemophilia B?

Haemophilia B is an inherited bleeding disorder where your blood doesn't clot properly due to a missing or faulty Factor IX protein, leading to prolonged bleeding.

What is etranacogene dezaparvovec?

It's a gene therapy treatment that aims to help your body produce the missing Factor IX protein, which can reduce bleeding episodes in people with haemophilia B.

Am I receiving new treatment in this study?

No, this study is a follow-up. You won't receive new treatment; it's for monitoring those who previously had the gene therapy.

كم من الوقت سأحتاج للبقاء في الدراسة؟

The study aims for long-term follow-up; the duration for you will depend on when you received your initial gene therapy treatment in the parent studies.

What is the purpose of this long-term study?

The main purpose is to understand the long-term safety and effectiveness of etranacogene dezaparvovec gene therapy for men with haemophilia B.

كيفية معرفة المزيد

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "Long-term Follow-up Study of Male Adults With Hemophilia B P… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.